Vident Investment Advisory LLC trimmed its holdings in Chemed Co. (NYSE:CHE) by 10.3% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,668 shares of the company’s stock after selling 1,458 shares during the quarter. Vident Investment Advisory LLC owned about 0.08% of Chemed worth $2,560,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Bank of Montreal Can lifted its stake in Chemed by 2.4% in the second quarter. Bank of Montreal Can now owns 3,311 shares of the company’s stock valued at $677,000 after buying an additional 77 shares during the last quarter. Strs Ohio lifted its stake in Chemed by 5.6% in the second quarter. Strs Ohio now owns 1,900 shares of the company’s stock valued at $388,000 after buying an additional 100 shares during the last quarter. Municipal Employees Retirement System of Michigan lifted its stake in Chemed by 4.1% in the second quarter. Municipal Employees Retirement System of Michigan now owns 3,850 shares of the company’s stock valued at $787,000 after buying an additional 150 shares during the last quarter. Great West Life Assurance Co. Can lifted its stake in Chemed by 2.2% in the second quarter. Great West Life Assurance Co. Can now owns 23,387 shares of the company’s stock valued at $4,780,000 after buying an additional 503 shares during the last quarter. Finally, World Asset Management Inc purchased a new stake in Chemed in the second quarter valued at approximately $216,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

Shares of Chemed Co. (CHE) opened at $234.76 on Tuesday. The company has a market capitalization of $3,810.29, a P/E ratio of 29.39, a PEG ratio of 5.05 and a beta of 1.16. The company has a current ratio of 0.50, a quick ratio of 0.48 and a debt-to-equity ratio of 0.15. Chemed Co. has a 52 week low of $151.23 and a 52 week high of $251.00.

Chemed (NYSE:CHE) last released its quarterly earnings data on Thursday, October 26th. The company reported $2.15 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.00 by $0.15. The firm had revenue of $417.40 million during the quarter, compared to analysts’ expectations of $414.34 million. Chemed had a return on equity of 27.69% and a net margin of 4.62%. Chemed’s revenue was up 6.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.73 earnings per share. research analysts forecast that Chemed Co. will post 4.73 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 4th. Shareholders of record on Monday, November 13th were given a $0.28 dividend. This represents a $1.12 annualized dividend and a yield of 0.48%. The ex-dividend date of this dividend was Friday, November 10th. Chemed’s payout ratio is 24.89%.

CHE has been the subject of several analyst reports. Oppenheimer upped their price target on Chemed from $220.00 to $225.00 and gave the stock an “outperform” rating in a research note on Friday, October 27th. Zacks Investment Research cut Chemed from a “buy” rating to a “hold” rating in a research note on Wednesday, September 13th. Royal Bank of Canada upped their price target on Chemed to $232.00 and gave the stock a “sector perform” rating in a research note on Tuesday, October 31st. KeyCorp restated a “hold” rating on shares of Chemed in a research note on Friday, October 27th. Finally, TheStreet upgraded Chemed from a “c+” rating to an “a-” rating in a research note on Friday, October 27th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $236.00.

In other Chemed news, Director Patrick P. Grace sold 500 shares of the company’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $201.48, for a total value of $100,740.00. Following the sale, the director now owns 4,515 shares of the company’s stock, valued at $909,682.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Naomi C. Dallob sold 750 shares of the company’s stock in a transaction on Tuesday, October 31st. The shares were sold at an average price of $222.09, for a total value of $166,567.50. Following the completion of the sale, the vice president now directly owns 9,097 shares in the company, valued at approximately $2,020,352.73. The disclosure for this sale can be found here. Insiders sold 46,179 shares of company stock valued at $10,729,699 in the last quarter. 4.90% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION NOTICE: “Chemed Co. (CHE) Shares Sold by Vident Investment Advisory LLC” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://www.thecerbatgem.com/2017/12/12/chemed-co-che-shares-sold-by-vident-investment-advisory-llc.html.

About Chemed

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Institutional Ownership by Quarter for Chemed (NYSE:CHE)

Receive News & Stock Ratings for Chemed Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Co. and related stocks with our FREE daily email newsletter.